Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Show more
Location: 259 Liberty Avenue, Staten Island, NY, 10305, United States | Website: https://www.acurxpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
6.569M
52 Wk Range
$3.80 - $44.00
Previous Close
$4.14
Open
$3.96
Volume
50,814
Day Range
$3.83 - $4.15
Enterprise Value
504.8K
Cash
6.064M
Avg Qtr Burn
-2.041M
Insider Ownership
8.12%
Institutional Own.
13.95%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ibezapolstat (IBZ) Details Clostridioides difficile infection | Phase 3 Initiation |